microRNA 4661 (MIR4661)

microRNA 4661 is a short, non-coding RNA molecule (~20–24 nucleotides) encoded by the MIR4661 gene in humans. It is transcribed by RNA polymerase II as a primary transcript, then processed by Drosha and Dicer to yield a mature miRNA that participates in the RNA-induced silencing complex (RISC). The mature miRNA binds target mRNAs via imperfect base pairing, usually resulting in translational inhibition or destabilization of the mRNA, thereby modulating gene expression. Recent research highlights miR-4661-5p, the major mature product, as a serum exosomal biomarker for early-stage hepatocellular carcinoma, with high diagnostic performance, and with potential relevance in breast cancer and possibly other conditions. No specific drugs target MIR4661 clinically, but it is being explored for its biomarker and therapeutic potential[2][3][1].

Other names

MIR4661hsa-mir-4661miR-4661miR-4661-5p

If drugs were to target MIR4661, anticipated mechanisms would include: - Antisense inhibition (antagomirs or anti-miRs to block function) - Mimic delivery (restoring its activity where suppressed)